Serveur d'exploration sur les relations entre la France et l'Australie - Analysis (Allemagne)

Index « Auteurs » - entrée « Florent Grange »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Florent Brunet < Florent Grange < Florent Lavergne  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 2.
Ident.Authors (with country if any)Title
000261 (2017) Paolo A. Ascierto [Italie] ; Michele Del Vecchio [Italie] ; Caroline Robert [France] ; Andrzej Mackiewicz [Pologne] ; Vanna Chiarion-Sileni [Italie] ; Ana Arance [Espagne] ; Céleste Lebbé [France] ; Lars Bastholt [Danemark] ; Omid Hamid [États-Unis] ; Piotr Rutkowski [Pologne] ; Catriona Mcneil [Australie] ; Claus Garbe [Allemagne] ; Carmen Loquai [Allemagne] ; Brigitte Dreno [France] ; Luc Thomas [France] ; Jean-Jacques Grob [France] ; Gabriella Liszkay [Hongrie] ; Marta Nyakas [Norvège] ; Ralf Gutzmer [Allemagne] ; Joanna Pikiel [Pologne] ; Florent Grange [France] ; Christoph Hoeller [Autriche] ; Virginia Ferraresi [Italie] ; Michael Smylie [Canada] ; Dirk Schadendorf [Allemagne] ; Laurent Mortier [France] ; Inge Marie Svane [Danemark] ; Delphine Hennicken [États-Unis] ; Anila Qureshi [États-Unis] ; Michele Maio [Italie]Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
000D76 (2015) Jean Jacques Grob [France] ; Mayur M. Amonkar [États-Unis] ; Boguslawa Karaszewska [Pologne] ; Jacob Schachter [Israël] ; Reinhard Dummer [Suisse] ; Andrzej Mackiewicz [Pologne] ; Daniil Stroyakovskiy [Russie] ; Kamil Drucis [Pologne] ; Florent Grange [France] ; Vanna Chiarion-Sileni [Italie] ; Piotr Rutkowski [Pologne] ; Mikhail Lichinitser [Russie] ; Evgeny Levchenko [Russie] ; Pascal Wolter [Belgique] ; Axel Hauschild [Allemagne] ; Georgina V. Long [Australie] ; Paul Nathan [Royaume-Uni] ; Antoni Ribas [États-Unis] ; Keith Flaherty [États-Unis] ; Peng Sun [États-Unis] ; Jeffrey J. Legos [États-Unis] ; Diane Opatt Mcdowell [États-Unis] ; Bijoyesh Mookerjee [États-Unis] ; Dirk Schadendorf [Allemagne] ; Caroline Robert [France]Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

List of associated KwdEn.i

Nombre de
documents
Descripteur
2Humans
2Intention to Treat Analysis
2Melanoma (drug therapy)
2Melanoma (secondary)
2Treatment Outcome
1Administration, Oral
1Aged
1Alanine Transaminase (blood)
1Antibodies, Monoclonal (administration & dosage)
1Antibodies, Monoclonal (adverse effects)
1Antineoplastic Agents (administration & dosage)
1Antineoplastic Agents (adverse effects)
1Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
1Antineoplastic Combined Chemotherapy Protocols (adverse effects)
1Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
1Biomarkers, Tumor (genetics)
1Colitis (chemically induced)
1DNA Mutational Analysis
1Diarrhea (chemically induced)
1Disease Progression
1Disease-Free Survival
1Double-Blind Method
1Drug Administration Schedule
1Female
1Follow-Up Studies
1Genetic Predisposition to Disease
1Hypophysitis (chemically induced)
1Imidazoles (administration & dosage)
1Imidazoles (adverse effects)
1Imidazoles (therapeutic use)
1Indoles (administration & dosage)
1Indoles (adverse effects)
1Indoles (therapeutic use)
1MAP Kinase Kinase Kinases (antagonists & inhibitors)
1MAP Kinase Kinase Kinases (metabolism)
1Male
1Melanoma (genetics)
1Melanoma (mortality)
1Middle Aged
1Mutation
1Oximes (administration & dosage)
1Oximes (adverse effects)
1Oximes (therapeutic use)
1Phenotype
1Prospective Studies
1Protein Kinase Inhibitors (administration & dosage)
1Protein Kinase Inhibitors (adverse effects)
1Protein Kinase Inhibitors (therapeutic use)
1Proto-Oncogene Proteins B-raf (antagonists & inhibitors)
1Proto-Oncogene Proteins B-raf (genetics)
1Pyridones (administration & dosage)
1Pyridones (adverse effects)
1Pyridones (therapeutic use)
1Pyrimidinones (administration & dosage)
1Pyrimidinones (adverse effects)
1Pyrimidinones (therapeutic use)
1Quality of Life
1Risk Factors
1Skin Neoplasms (drug therapy)
1Skin Neoplasms (genetics)
1Skin Neoplasms (mortality)
1Skin Neoplasms (pathology)
1Sulfonamides (administration & dosage)
1Sulfonamides (adverse effects)
1Sulfonamides (therapeutic use)
1Surveys and Questionnaires
1Survival Rate
1Time Factors

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Florent Grange" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i  \
                -Sk "Florent Grange" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Allemagne
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Florent Grange
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024